|Bid||8.00 x 300|
|Ask||33.99 x 200|
|Day's Range||33.31 - 33.80|
|52 Week Range||18.30 - 42.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.50|
NEW YORK , March 16, 2018 /PRNewswire/ -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on March 21 st and 22 nd , featuring live ...
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Hutchison China MediTech Limited (NASDAQ:HCM), with a market cap of US$4.50B, are often out ofRead More...
Hutchison China MediTech Limited has initiated a Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients with epidermal growth factor receptor gene amplification in China.
Investors tend to look for stocks that have a strong future outlook. Why invest in something that will grow slower than the rest of the market? In terms of profitabilityRead More...
Hutchison China MediTech Limited has completed patient enrollment of FALUCA, its Phase III pivotal trial of fruquintinib in advanced, third-line, non-small cell lung cancer patients in China.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hutchison China MediTech Ltd. Here are 5 ETFs with the largest exposure to HCM-US. Comparing the performance and risk of Hutchison China MediTech Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)
Hutchison China MediTech Limited has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3, that has met its primary endpoint in several Phase II and III clinical trials in China for the treatment of colorectal, lung and gastric cancers.
Hutchison China MediTech Limited’s (NASDAQ:HCM) most recent return on equity was a substandard 7.52% relative to its industry performance of 16.15% over the past year. HCM’s results could indicate aRead More...
Hutchison China MediTech Limited has initiated FRUTIGA, a pivotal Phase III clinical trial of fruquintinib in combination with paclitaxel for the treatment in advanced gastric or gastroesophageal junction adenocarcinoma patients in China.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURI
China-based cancer and immunology drug specialist Hutchison China MediTech, or Chi-Med, said it aimed to offer $262 million of American Depositary Shares, subject to market conditions, to help fund development ...
Hutchison China MediTech Limited announced today that it intends to offer, subject to market and other conditions, US$262.0 million of American Depositary Shares , each representing one-half of one ordinary share, par value US$1.00 each of Chi-Med , on the Nasdaq Global Select Market .
LONDON, UK / ACCESSWIRE / October 18, 2017 / Data presented at the World Conference on Lung Cancer (WCLC) on combination approaches to treat resistant EGFR-driven non-small cell lung cancer (NSCLC) highlight ...
Hutchison China MediTech Limited and AstraZeneca PLC today presented preliminary safety and clinical activity data of savolitinib when given in combination with either Tagrisso® or Iressa® in two Phase Ib/II proof-of-concept trials conducted in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET-amplification who had progressed following first-line treatment ...
Hutchison China MediTech Limited today reported preliminary clinical activity, safety, and tolerability data of fruquintinib, an investigational selective inhibitor of vascular endothelial growth factor receptor given in combination with Iressa®.
Hutchison China MediTech Limited today announces that Professor Mok, Shu Kam Tony has been appointed as Independent Non-Executive Director and member of the Technical Committee with effect from October 12, 2017.
Hutchison China MediTech Limited (AIM:HCM) generated a below-average return on equity of 7.52% in the past 12 months, while its industry returned 9.01%. HCM’s results could indicate a relatively inefficientRead More...
Hutchison China MediTech Limited announced that new clinical data on three of its novel tyrosine kinase inhibitors, fruquintinib, savolitinib and theliatinib, were presented at the 20th Annual Meeting of the Chinese Society of Clinical Oncology , held in Xiamen, China, from September 26 to 30, 2017.
Hutchison China MediTech Limited today announces that non-small cell lung cancer proof-of-concept clinical data on two of its novel tyrosine kinase inhibitors , savolitinib and fruquintinib, will be presented at the 18th World Conference on Lung Cancer , to be held in Yokohama, Japan from October 15 to 18, 2017.
Hutchison China MediTech Limited (AIM:HCM), a pharmaceuticals, biotechnology and life sciences company based in Hong Kong, See our latest analysis for HCM What is HCM worth? HCM appears to beRead More...
Hutchison China MediTech Limited has initiated a Phase I clinical trial of HMPL-689 in China. HMPL-689 is a novel, highly selective and potent small molecule inhibitor targeting phosphoinositide-3 kinase delta isoform , a key component in the B-cell receptor signaling pathway.
Categories: Yahoo FinanceGet free summary analysis Hutchison China MediTech Ltd. reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of Hutchison China MediTech Ltd. – OncoMed Pharmaceuticals, Inc. and OrganiGram Holdings Inc (OMED-US and OGRMF-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more (Read more...)
Hutchison China MediTech Limited , the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the global market, today announces its unaudited financial results for the six months ended June 30, 2017.